跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
Health Canada
/
MYLAN-ABACAVIR/LAMIVUDINE
Authorized
STANDARD
MYLAN-ABACAVIR/LAMIVUDINE
Mylan Pharmaceuticals ULC
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
a97d681be2690af3
Company
Mylan Pharmaceuticals ULC
Type
Standard
Approval Details
Approval Id
a97d681be2690af3
Drug Approval Canada Name
MYLAN-ABACAVIR/LAMIVUDINE
Product Name
MYLAN-ABACAVIR/LAMIVUDINE
Status
Marketed
Status Date
2016-03-29
Original Market Date
2016-03-29
Din
02450682
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
08:18.08.20
Atc Original
J05AR02 LAMIVUDINE AND ABACAVIR
Atc Name
j 05 ar 02
Aig Number
0251241001
Company Name
Mylan Pharmaceuticals ULC
Company Address
85 Advance Road, Etobicoke, Ontario, Canada, M8Z 2S6
Active Ingredients
LAMIVUDINE
300 MG
ABACAVIR (ABACAVIR SULFATE)
600 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
a97d681be2690af3
Type
Standard
Back to Health Canada Approvals
MYLAN-ABACAVIR/LAMIVUDINE - Health Canada Drug Approval Details